Employee share option scheme

Posted on Oct 17, 2017

Oslo (Norway), 17 October 2017 – In accordance with the authorisation granted by the Annual General Meeting 29 May 2017, the Board of Directors of PCI Biotech Holding ASA has awarded a total of 90,000 share options to key employees.  The share options are allotted to the newly hired Chief Medical Officer, Hans Olivecrona. Each share […]

PCI Biotech receives US Orphan Drug Designation for fimaporfin in the treatment of bile duct cancer (cholangiocarcinoma)

Posted on Oct 5, 2017

Oslo, 4 October 2017 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its lead product candidate, fimaporfin, for the treatment of patients suffering from cholangiocarcinoma (bile duct cancer). This patient population has no approved treatment alternatives today […]

Initial clinical results from Phase I indicate that vaccination with fimaVacc enhances cellular immune responses

Posted on Sep 12, 2017

Oslo (Norway), 12 September 2017 – PCI Biotech (OSE: PCIB), a cancer focused clinical-stage company developing innovative therapeutics that address significant unmet medical needs today announced that the first immune response results from the fimaVACC Phase I study in healthy volunteers indicate enhanced overall T-cell responses at tolerable dose levels. The clinical data cover more […]